SLC6A1 and epilepsy: Specifically, the BGT1/GAT1 mixed inhibitor EF1502 and the BGT1 selective inhibitor RPC-425 (Fig. 1) [20] have been found to present anti-seizure effects in mouse models, suggesting a role for BGT1 in epilepsy [20–23].